Webinar Series: Energy for sustainable development in Africa in the post-COVID19 world – looking for the New Normal
Webinar 2: Sustainable Energy for Africa: transition through growth. How to boost output, improve access and reduce impact on the nature and society? Technologies, scenarios, strategies, sources of finance and business models.
Africa, particularly sub-Saharan Africa, has generally low levels of socio-economic development and energy usage. The COVID-19 outbreak and its consequent economic downturn present additional challenges and pose questions requiring urgent answers. Success of the pandemic measures depend upon, among other elements, on a strategic vision reflecting current situation and future uncertainties; and aligning interests of all stakeholders. In order to build such strategic vision, we have invited leading experts in our webinars to facilitate information gathering and to generate ideas for further work on strategies development and stakeholders’ engagement necessary for the continent’s energy transition in the post-COVID-19 world.
Reflexiones sobre la Judicialización de la Salud en America Latina
Cuales son las causas de la problemática de la judicialización de la salud? Que efectos provoca sobre el sistema? Se discutira esta temática a partir del análisis de jurisprudencia y regulación en Argentina, Colombia y Ecuador.
The COVID-19 Pandemic: Intellectual Property Management for Access to Diagnostics, Medicines and Vaccines
Developing countries and LDCs in particular in Africa are especially vulnerable to the unfolding effects of the COVID-19 pandemic. A priority area for global collaboration is to ensure that diagnostics, vaccines and medicines are made available, affordable and accessible worldwide. There is currently no vaccine and no proven safe and effective direct therapy for COVID-19. There is also the need to accelerate testing capacity and tools in developing countries and LDCs with increased access to low-cost diagnostics. The approach to the management of intellectual property rights by research institutions, pharmaceutical and biotech companies and R&D funders will decisively affect availability and access, as well as the transfer of technology and know-how. Governments must ensure that they have legislative and procedural frameworks in place to enable them to over-come, consistently with the TRIPS Agreement, any patent, data exclusivity and trade secret barriers to procure and produce COVID-19 diagnostics, vaccines, medicines and other therapeutics.
